C19 is useful to detect CEA in malignant adenocarcinoma, notably in the gastro-intestinal tract. Clinical relevance is also found in breast-, lung-, prostatic-,ovarian- and other carcinomas of endodermal origin (stomach, liver, pancreas). Contrary to some other antibodies, C19 stains granulocytes in blood smears and tonsils, as well as epithelial cells.
Suitable for Immunohistochemistry on paraffin embedded sections (0.1 μg/mL, 1/4000). Microwave pretreatment forantigen retrieval is recommended. Suggested positive control: Human colon carcinoma. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Protocol
Protocol with formalin-fixed, paraffin-embedded sections: The whole procedure is performed at room temperature
Restrictions
For Research Use only
Reconstitution
Restore with 0.5 mL distilled water.
Concentration
0.4 mg/mL
Buffer
PBS, pH 7.2 with 10 mg/mL bovine serum albumin (BSA) as a stabilizer and 0.01 % thimerosal as a preservative.
Preservative
Thimerosal (Merthiolate)
Precaution of Use
This product contains thimerosal (merthiolate): a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
CEA is a glycoprotein of 180 kDa m.w. It is a normal constituent of the glycocalix of embryonic endodermal epithelium and is produced mainly in the mucosa of the normal colon.Synonyms: CEA, Carcinoembryonic antigen, Carcinoembryonic antigen-related cell adhesion molecule 5, Meconium antigen 100